Edmond

Two Research Leaders from CHOP Elected to National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023
Edmond, Health, National Academy of Medicine, Doctor of Philosophy, Epidemiology, Death, LCHS, Research, Public, National academy, Nephrology, Pediatrics, PI, NAM, Patient-Reported Outcomes Measurement Information System, Pediatric Research, Institute of Medicine, Nepal, Perelman School of Medicine at the University of Pennsylvania, University, Kidney, CHOP, Medicine, Hospital, Philadelphia, Society, Society for Pediatric Research, Chronic kidney disease, PROMIS, Policy, Science, Natural history, Child, Children's Hospital of Philadelphia, NIH, Management, Nursing, MD

PHILADELPHIA, Oct. 9, 2023 /PRNewswire/ -- Two renowned experts from Children's Hospital of Philadelphia (CHOP) have been elected to the National Academy of Medicine (NAM), effective October 1, 2023. CHOP Chief Scientific Officer Susan Furth, MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest, MD, PhD, have both been recognized for outstanding professional achievement. An election to NAM is considered one of the highest honors in health and medicine.

Key Points: 
  • CHOP Chief Scientific Officer Susan Furth , MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest , MD, PhD, have both been recognized for outstanding professional achievement.
  • In addition to her nephrology research, Dr. Furth is Chief Scientific Officer and Executive Vice President at CHOP, where she oversees the CHOP Research Institute and its more than 1,000 investigators and 2,600 employees.
  • He is the Director and Founder of PEDSnet , a national pediatric learning health system, which is one of the PCORnet Clinical Research Networks.
  • Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the NAM addresses critical issues in health, science, medicine, and related policy.

The Paulson Family Foundation Donates $27m for a New Building at Hebrew University's School of Computer Science and Engineering

Retrieved on: 
Thursday, September 28, 2023
Learning, Al-Quds, Hebrew University of Jerusalem, University, Lightricks, Education, Culture, UNSW School of Computer Science and Engineering, Mobileye, Research, Paulson & Co., Science, American Friends of the Hebrew University, Student, Rachel, School, Economic development, Edmond, Health, Computer science, Nursing, Engineering

The Hebrew University's School of Computer Science and Engineering has been the birthplace of some of the world's leading hi-tech companies, including Mobileye and Lightricks.

Key Points: 
  • The Hebrew University's School of Computer Science and Engineering has been the birthplace of some of the world's leading hi-tech companies, including Mobileye and Lightricks.
  • This gift from the U.S.-based Paulson Family Foundation will enable the construction of the fourth building in the computer science complex, thus expanding and upgrading the School's learning spaces and research laboratories.
  • The Paulson Family Foundation was founded in 2009 by John Paulson, President of Paulson & Co., a global investment company.
  • This gift will ensure that the Hebrew University has the resources to meet the growing demand for computer science and engineering education."

The FNIH Awards 2023 Charles A. Sanders, M.D., Partnership Award to NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family

Retrieved on: 
Monday, September 18, 2023
Children, Biotechnology, Baby, Maternity, Other Health, Health, Women, Pharmaceutical, Research, Consumer, Science, Clinical Trials, GSK, DNA, The New England Journal of Medicine, FNIH, Prevalence, Awards ceremony, Kidney cancer, Molina Healthcare, Clinical trial, Global Smoke-Free Partnership Award, Dean, Woman, Biomedical sciences, PRIORITY, Biomarker, NICHD, Lung, Doctor of Philosophy, Bill & Melinda Gates Foundation, Person, Bangladesh Technical Education Board, National Institutes of Health Clinical Center, Organization, NHLBI, Azithromycin, Charles, MD, Patient, Tuberculosis, World Cultural Council 29th Award Ceremony, Child, Anemia, Human development, Bill, Edmond, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Transplant, Death, NIH, National Heart, Lung, and Blood Institute, Renal cell carcinoma, Nursing, Pharmaceutical industry

The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .
  • The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the National Institutes of Health (NIH).
  • The Azithromycin Prevention in Labor Use Study (A-PLUS) assessed low-cost, sustainable interventions to improve maternal and child health.
  • The Charles A. Sanders, M.D., Partnership Award is named for the former Chairman of the FNIH Board of Directors.

The FNIH Awards 2023 Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., from Memorial Sloan Kettering Cancer Center for Pancreatic Cancer Research

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Memorial Sloan Kettering Cancer Center, Pancreatic cancer, American Society for Clinical Investigation, GSK, Survivor, Trailblazer, FNIH, University, Awards ceremony, Disability, Neoplasm, Physician, Cancer, University of Iowa, American Physician Scientists Association, Biomedical sciences, AAP, Research, Bangladesh Technical Education Board, Messenger, Association of American Physicians, Charles, Global Smoke-Free Partnership Award, Patient, World Cultural Council 31st Award Ceremony, MSK, Edmond, Society, Pharmaceutical industry, Vaccine

The Foundation for the National Institutes of Health (FNIH) has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D.
  • , at Memorial Sloan Kettering Cancer Center (MSK), for his groundbreaking research on immunotherapies for pancreatic cancer.
  • This pioneering work has the potential to transform the treatment of pancreatic cancer, one of the deadliest malignancies, and provide proof of concept for future cancer vaccines.
  • He is also immunology group leader in the David M. Rubenstein Center for Pancreatic Cancer Research at MSK.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Konica Minolta Announces Significant Expansion of Dynamic Digital Radiography Across Multiple Facility Types and Clinical Care Areas

Retrieved on: 
Monday, July 10, 2023
Amos, Barium, Partnership, DDR, Workflow, Patient satisfaction, Pelvis, Anatomy, Claustrophobia, Doctor of Philosophy, Stomach, Lung transplantation, MRI, Motion, Konica Minolta, Hospital, Patient, Digital radiography, Emory Healthcare, Hearing, Automatic exposure control, MSK, Fluoroscopy, Edmond, Injury, Health, Alta Bates Summit Medical Center, Medical imaging, Radiology

Unlike fluoroscopy, DDR is a series of individual digital X-ray images acquired at high speed and low doses, allowing the visualization of anatomy in motion.

Key Points: 
  • Unlike fluoroscopy, DDR is a series of individual digital X-ray images acquired at high speed and low doses, allowing the visualization of anatomy in motion.
  • DDR has broad utilization across multiple clinical care specialties, including pulmonary, musculoskeletal, lung transplantation, swallowing studies and more, and is being used for both contrast and non-contrast studies.
  • Greg Miner, Appleton Area Health Chief Executive Officer, says, “To bring this type of diagnostic care to Appleton is truly remarkable.
  • DDR is the type of technology you would expect to find in only large metropolitan areas in our region.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

The Michael J. Fox Foundation Remembers Visionary Philanthropist Mrs. Lily Safra

Retrieved on: 
Friday, July 22, 2022
Goal, Brain, Diagnosis, View, Education, The Michael J. Fox Foundation, Awareness, For Hope, Industry, Instagram, Twitter, Foundation, CEO, Culture, Parkinson's disease, Research, Genetics, Government, Partnership, Religion, Neurology, Board, Movement disorders, Multimedia, Volunteering, LEAPS, Organization, Leadership, Quality of life, Clinical trial, Fox Trial Finder, Genome-wide association study, Grief, Disease, Hope, Board of directors, Science, Memory, LinkedIn, Patient, NEW, Edmond, Program, Growth, MJFF, Lists of diseases, Medicine, Management, Pharmaceutical industry, PD, Facebook

Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87

Key Points: 
  • Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87
    Mrs. Safra's transformative generosity and leadership supported a wide range of The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) mourns the loss of visionary philanthropist and Foundation Board member Lily Safra , who passed away on Saturday, July 9, 2022 in Geneva, Switzerland.
  • As chairwoman of the Edmond J. Safra Foundation, Mrs. Safra provided transformative support to hundreds of organizations around the world in the name of her late husband, Edmond J. Safra.
  • Edmond J. Safra lived with Parkinson's disease (PD), and Mrs. Safra was deeply committed to finding a cure.